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Attention-deficit and hyperactivity disorder (ADHD) is a widespread neurodevelopmental
disorder in children and adolescents, persisting into adulthood in a majority of
them. ADHD and substance use disorders (SUDs) commonly co-occur in the clinical
adult population. The higher-than-normal prevalence rates of SUDs in people with
ADHD indicate increased risk for developing SUD. This narrative review deals with
the question of whether or not adults with both disorders should be treated with
methylphenidate (MPH), addressing specific issues surrounding this form of treatment.
MPH is considered as first-line pharmacotherapy for ADHD. However, because of
its stimulant-like reinforcing properties, MPH has a significant addictive potential to
which persons with SUDs are especially susceptible. Appropriate treatment is therefore
complex. Because of concerns about misuse and diversion of MPHmedication, clinicians
may be reluctant to use MPH to manage ADHD symptoms in these patients. However, it
is essential to diagnose and treat ADHD adequately as appropriate therapy reduces the
impairments, as well as the risk of developing comorbid disorders and poor treatment
response. MPH should not be deprived of these patients because of the risk for misuse,
especially as several strategies can be applied to minimize this risk. To conclude, carefully
applied guideline-based diagnostics to clarify the potential presence of ADHD as well
as a responsible prescription practice in a well-defined therapeutic setting with reliable
monitoring of medication intake and regular consultations are essential conditions for a
safe and proficient MPH treatment of ADHD in patients with SUD.
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The prevalence of attention-deficit and hyperactivity disorder
(ADHD) in children and adolescents is estimated to be between
2 and 7% (1), whereby some studies found prevalence rates
up to 16% in certain age groups (2). The prevalence rates
vary depending on the underlying classification system, and
boys are diagnosed about two to three times more often with
ADHD than girls (3–5). Already during early infancy, people
with ADHD often exhibit signs, such as frequent crying, feeding
and sleeping problems, restless sleep, and excessive unrest (6–8).
Subsequently, the key features of ADHD manifest inattention,
impulsivity, and hyperactivity.
ADHD is a multifactorial, clinically heterogeneous
neurodevelopmental disorder (9) caused by interplay between
genetic and environmental factors (10). It is assumed to result
from suboptimal dopamine levels in the synaptic cleft due to
overexpression of the presynaptic dopamine transporter (DAT)
(11). Numerous studies have proven a familial aggregation of
ADHD (5, 12). Environmental risk factors are, e.g., prenatal
exposure to alcohol and tobacco, premature birth, critical birth
circumstances, and incongruities in parent–child interactions,
such as difficulties in feeding the infant, etc. (2, 12). Based on
genetic predisposition and psychosocial risks, ADHD leads,
among others, to neurocognitive/behavioral problems due to
neurobiological dysregulation. These problems manifest mainly
in the area of attention and executive functions (2, 13). People
with ADHD show deficits in attention intensity and selectivity, in
executive inhibitory control (of, e.g., motor action or prepotent
responses) and therefore in self-regulation, as well as in memory
functions, especially in short-term/working memory (2). They
therefore struggle with continuous vigilance and attention, are
easily distracted by internal and/or external stimuli, experience
themselves as “forgetful,” and express difficulty in self-organizing
and performing their daily routines. Other neurocognitive
performances are usually not affected.
The long-prevailing view that ADHD is a disorder of
childhood and adolescence, phasing out in adulthood, has been
refuted (14–16). Even in adulthood ADHD is a disorder that
leads to several mental problems and serious social issues
(17). According to current knowledge, in 60% of the affected
individuals, some or even all symptoms of the disorder will
persist into adulthood. Depending on the study, the prevalence
of ADHD in adults ranges from 1 to 4% (18, 19), with
less pronounced gender differences than in children and
adolescents (20).
Although the neurobiological functional deficits remain the
central problem for all age groups, the severity and course
of the disorder in adults are extremely heterogeneous (19).
Abbreviations: ADHD, attention-deficit and hyperactivity disorder; SUD,
substance use disorder; DAT, dopamine transporter; MPH, methylphenidate;
OUD, opioid use disorder; OAT, opioid agonist treatment; VTA, ventral
tegmental area; PFC, prefrontal cortex; ACC, anterior cingulate cortex; OROS-
MPH, osmotic-release oral systems methylphenidate; LDX, Lisdexamfetamine
dimesylate; ASRS v1.1, adult self-report scale.
Impairments in everyday life are often more multifaceted
than in children, whereas hyperactivity fades often into the
background. Issues resulting from attention deficits are much
more characteristic in adults so that difficulties in performing
daily routine tasks often lead to severe problems at home, at
work, and in social relationships (13). Moreover, the suboptimal
regulation of affect and impulse control often impair social
interactions, increasing the psychological strain of the affected
people and their living environment and favoring the occurrence
of other mental disorders.
This article briefly reviews existing literature on
methylphenidate (MPH) treatment of adult ADHD in persons
with substance use disorders (SUDs), especially with opioid
use disorder (OUD). It takes up on specific problems, such as
misuse and diversion of MPH, which are associated with MPH
therapy in these patients. It also aims to give recommendations
on diagnostics, therapy, and treatment settings, when dealing
with these issues.
METHODS
This narrative review is predominantly based on a MEDLINE
database search. Additionally, importance was given to include
guidelines for clinical practice, such as NICE guidelines (21) or
consensus statements of experts (22, 23), in order to address
specific issues, which arise during the treatment of patients with
ADHD as well as SUD.
RESULTS
ADHD and SUDs
Co-occurring ADHD and SUDs are routinely encountered in
clinical settings (24). Studies have shown that the prevalence rates
of SUDs are two to four times higher in people with ADHD
than in the normal population (25, 26). In clinical samples,
one-fifth of all alcohol-dependent and up to one-third of all
cocaine-dependent patients meet criteria for adult ADHD (27,
28). In patients receiving opioid agonist treatment (OAT), the
prevalence rates range between 20 and 25% (17, 29, 30). Overall,
the prevalence rates of adult ADHD in SUD treatment settings
range up to 24% (30). Both the severity and persistence of ADHD
symptoms seem to influence the risk of developing an SUD and
to reduce the effectiveness of treatment (31).
The relationship between ADHD and SUD is complex.
As psychoactive substances reduce, imitate, or aggravate the
symptoms of ADHD, differentiating between both disorders is
challenging, which impedes the research in this field (32, 33).
There is an ongoing debate whether common genetic factors or
the attempt of self-medication causes the increased vulnerability
for SUDs in persons with ADHD (15, 34). However, there seems
to be no preference for any specific SUD (28, 35, 36).
Studies exploring common neuronal pathways in ADHD
and SUDs indicate that anomalies in circuits related to reward
processing, especially delayed reward processing (37, 38), might
be present in both disorders (39, 40). Circuits related to reward
processing are the mesolimbic and mesocortical pathways. The
mesolimbic pathway involves mainly dopaminergic projections
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from the ventral tegmental area (VTA) in the midbrain
through the median forebrain bundle to the nucleus accumbens
and the limbic system with amygdala, hypothalamus, and
hippocampus (41). Particularly, the mesoaccumbens dopamine
pathway projecting from the VTA to the nucleus accumbens
is associated with reward and motivation (42). The nucleus
accumbens, a major component of the ventral striatum, is
associated with the outcome evaluation of the reward (43). The
mesocortical pathway involves mainly dopaminergic projections
from the VTA to the prefrontal cortex (PFC) (44) and the
anterior cingulate cortex (ACC). These structures are involved
in executive functioning, such as decision-making or impulse
control (45). In ADHD and SUDs, similar deficits in dopamine
activity in these regions were found (39, 46). Positron emission
tomography studies showed that ADHD and SUD seem to
be associated with a reduced D2/D3 receptor availability in
the midbrain, caudate nucleus (part of dorsal striatum), and
hypothalamus (39, 42, 46). DAT binding was diffusely decreased
across nucleus accumbens, midbrain, left caudate nucleus, and
hypothalamus (39). PFC is also interconnected to the caudate
nucleus, which plays an important role in procedural learning
and inhibitory control of action (47). Functional magnetic
resonance imaging studies suggest a reduced activation in
frontostriatal brain regions (46). Furthermore, underactivity in
the ACC and orbitofrontal cortex was associated with both
ADHD and SUD symptoms (39). A meta-analysis reported
reduced ACC gray matter volumes in adults with ADHD (48).
Also, smaller right putamen and right cerebellum gray matter
volumes were reported in adult ADHD (49). In people with
ADHD and cocaine use disorder, Wingen et al. reported smaller
occipital cortical gray matter volumes and reduced volumes in
the putamen compared to people with ADHD (49).
Diagnostics and Therapy
Appropriate diagnostic workup and therapy of adult ADHD is
important and necessary. First, the disorder is common but often
remains unrecognized (22). Second, it leads to severe mental
health and social impairments. Third, ADHD increases the risk
of developing many other mental disorders, especially SUDs,
affective disorders, anxiety disorders, and personality disorders
(19). Fourth, the syndrome is well-treatable, and therapy reduces
the risk for comorbid disorders, psychosocial problems, and
treatment failure due to poor treatment response (2, 50).
Compared to children and adolescents, there is a great backlog
in the diagnostics and therapy of ADHD in adults (32). To
diagnose ADHD in adults, it is essential that the core symptoms
started before the age of 7 [or 12 according to Diagnostic and
Statistical Manual of Mental Disorders (DSM-5)] and are, at
least in part, still present in adulthood. The diagnostic process
should be performed, if possible, under abstinent conditions.
Also, the individuals in OAT should be well-adjusted to the
medication (51), so that the present symptoms can be clarified in-
depth and assessed reliably according to valid diagnostic criteria
[DSM-IV/DSM-5/International Classification of Diseases, 10th
Revision (ICD-10)].
To ensure a careful and comprehensive evaluation for possible
ADHD, a guideline-based diagnostic procedure is recommended
in current clinical practice (21). Although ICD-10 offers the
possibility to code the presence of ADHD, the criteria for adults
are not explicitly mentioned. Diagnosis based on guidelines
includes the developmental psychopathology of ADHD by
stating the collection of retrospective symptoms as an integral
part of the diagnosis.
According to NICE guidelines (21), the diagnostic evaluation
consists of multiple phases with different aims. It requires
patience, time, and the inclusion of several methods and
sources of information. For diagnosis and treatment, it is
always important to reconstruct the individual course of the
disorder as precisely as possible. The purpose of a thorough and
detailed psychiatric history is to identify individual problems
considering possible comorbid mental disorders, the history
of development of the individuals, and their family of origin.
Already the history may indicate the presence of ADHD. The
clinical impression is very important, but it is not sufficient
to diagnose ADHD. For differential diagnosis and for assessing
other mental disorders apart from the clinical impression, the
use of structured instruments (e.g., Structured Clinical Interview
for DSM-IV/DSM-5) is recommended. In patients with SUD, a
thorough assessment of the current SUDs is essential to evaluate
the influence of substance use on ADHD symptoms (52).
The next step is to collect a complete medical history and
to perform a physical examination to exclude organic causes,
such as thyroid disease, seizure disorder, or sleep disorder. To
assess former and current symptoms, parents/siblings, and other
important persons of trust should be interviewed. Validated
structured interviews, such as Conners’ Adult ADHD Diagnostic
Interview for DSM-IV (53) or the Diagnostic Interview for
ADHD in adults (54) can be used for this purpose.
In a following step, disorder-relevant symptoms and their
manifestation in individuals are assessed by using standardized
methods for detailed assessment. For this purpose, there are
several validated instruments available in different languages,
such as Adult ADHD Self-Report Scale and the short version for
screening, Wender-Utah-Rating-Scale for childhood symptoms,
or Conners’ or Brown’s scale for current symptoms. The
Conners’ or Brown’s scale is recommended to assess the
magnitude of the impairments caused by ADHD. As they
are normed (55), a severity classification (mild, moderate, and
severe) can be conducted by comparing the results with the
norm population. Alternatively, there are also batteries (e.g.,
Homburger ADHD scales for adults) available, which cover all
relevant instruments (56).
Finally, a neuropsychological assessment provides relevant
information about the general level of cognitive performance
and existing neurocognitive deficits. Mainly neuropsychological
tests aiming at attentional and executive functions as
well as tests to measure various aspects of intelligence
are used.
The decision for a therapy, respectively, or the choice of
a specific treatment depends on the severity of the current
situation, mental and social impairments, present comorbid
disorders, the relevance of the symptoms in performing daily
routine tasks, and existing resources (23). Ideally, the treatment
should include several components, such as pharmacotherapy,
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cognitive behavioral therapy in individual or group format,
psychoeducation, and peer support (57). Pharmacotherapy and
behavioral therapy seem to have similar therapeutic effects on
ADHD symptoms in adolescents (23). In adults with ADHD and
SUD, a combination of pharmacotherapy and psychotherapy is
recommended (22, 58, 59). When it comes to pharmacotherapy,
however, treatment with stimulants is the therapy of first
choice (2, 50).
Methylphenidate
MPH is a centrally acting psychostimulant (60) that is subject
to the narcotics law. It is approved for the treatment of ADHD
in children from 6 years of age, adolescents, and adults, as
well as for the treatment of sleep disorders (e.g., excessive
daytime sleepiness, narcolepsy) (61). In addition, off-label use
of MPH to treat depression is also practiced (61). There
are various immediate- and sustained-release preparations of
multiple brands available for oral or transdermal administration.
MPH unfolds its stimulant, indirectly sympathomimetic
effects by inhibiting presynaptic reuptake of dopamine and
noradrenaline (61). Unlike classical reuptake inhibitors, it also
induces rapid and significant rises in striatal (62) and accumbal
(63) dopamine efflux, which seems to play a key role for the
therapeutic effect of MPH (11). MPH leads to an upregulation
of the frontoparietal executive function network and the
temporoparietal attentional network, which is associated with
improved attention in children with ADHD and better inhibitory
control in the PFC (64). The calming effect of MPH in patients
with ADHD is most likely connected with the improvement of
dopamine deficiency (65). MPH has a high affinity toward the
DAT, which is comparable to that of cocaine (65). According to
Heal (62), “MPH and cocaine act as ‘inverse agonists,’ reversing
the usual direction of dopamine transport by DAT” (66).
Neuropharmacobehavioral studies of injected MPH and
cocaine revealed not only similarities, but also significant
differences between the two substances (67–69). For both drugs,
the fast uptake in the striatum paralleled the “high” experience
but only for cocaine the decline in the “high” corresponded to the
brain clearance rate. In contrast, for MPH, the “high” decreased
as rapidly as for cocaine despite significant striatal binding of the
drug, suggesting that acute tolerance to the reinforcing effects of
MPH had occurred (67, 69). The slow brain clearance of MPH
may therefore limit its misuse potential (70).
Misuse Potential of MPH
The misuse liability of MPH is well-known. In the literature,
mostly intravenous and nasal administrations, which led
to substance- or administration-specific complications, are
described as cases of misuse (70). Complications of such
administrations, particularly intravenous, with crushed tablets
include local or vascular infections, foreign body reactions,
granulomas in the lungs, and pulmonary arterial hypertension
due to the blockage of the lung circulation (71–73). Studies that
investigated the narrow path between the therapeutic impact and
the misuse-supporting reinforcing effect of MPH found strong
hints for the euphoric potential of MPH in people with as well
as without histories of SUD (74, 75). While a slow increase
in serum concentrations shows therapeutic effects, a rapid and
steep increase results in subjective reinforcing effects (76, 77).
Therefore, a rapid onset of action and high concentrations in the
body are essential to get the “high,” which can be achieved by
intravenous or nasal administration or by the intake of very high
doses (76). Recent data collected in a sample of patients in OAT
suggest that the need for a rapid onset of action is an important
reason for MPH misuse in this population (68). However, an
analysis of two studies, which investigated the subjective effects
of osmotic-release oral systems MPH (OROS-MPH) showed
substance use severity did not significantly affect the euphoric
effects of OROS-MPH (78).
Misuse and Diversion of MPH in ADHD
Patients
Misuse and diversion are inherent risks of prescribing controlled
substances, and a substantial minority of patients with prescribed
MPH will misuse their own prescription or divert their
medications to others (75). In recent years, an increase of cases
of misuse and diversion has been reported, which goes along
with an increase of ADHD diagnoses and thus prescription of
MPH (71). However, the frequency of misuse in people with
ADHD is not clear. In a prospective cohort study with patients
who received prescribed MPH, 22% of the patients with ADHD
reported to have misused MPH at least once (79). In another
survey of a specialized institution, 14% of the patients with
ADHD reported to have misused MPH (predominantly nasal) or
another prescribed stimulant (80). In a national US survey, 8.9%
of the participants with a prescription for ADHD medication
reported to have sold, traded, or given away their medication
(81).Mostly older adolescents and adults who consume also other
psychotropic substances or have other behavioral disorders are at
risk of doing so (71, 79, 82). A recent study suggests that MPH
may also be misused by a substantial proportion of methadone-
maintained patients (83). A survey in France showed that ∼46%
ofMPH acquisitions by persons with substance dependence or on
OAT were illegal (84). However, the diversion/misuse of OROS-
MPH seems not to be affected by the substance use severity of the
patients (78).
DISCUSSION AND CONCLUSION
MPH Therapy for Patients With ADHD and
SUD
It has not yet been clarified to what extent ADHD treatment
with MPH contributes to the development of SUDs. Current
evidence is based on secondary analyses as prospective studies,
to our knowledge, are still missing. The existing results are
inconsistent; however, they do not indicate that MPH contributes
to the development of SUDs. On the contrary, treating ADHD
patients with MPH may reduce their risk for SUD (77, 85, 86).
According to a meta-analysis, ADHD patients treated with MPH
in their childhood show a reduced risk of developing SUD by a
factor of 1.9 compared to untreated patients (79). Studies using
data from large databases and registries showed that medication
treatment of ADHD, mostly with stimulants, was associated with
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a significantly reduced risk of SUD outcomes (87–89) and that
within individuals this reduction in risk of SUD outcomes is
related to periods of adherence to the medication prescribed (87,
89). However, stimulant medication was neither associated with
an increased nor decreased risk for SUD diagnoses in another
study (90). A meta-analysis with data from two of these studies
(88, 89) showed that the risk of substance use outcomes was
reduced; however, it did not attain statistical significance (91).
Research among patients in OAT with ADHD suggests that a
cotherapy with MPH not only reduces ADHD symptoms and
improves psychosocial functioning but also does not worsen the
course of substance use (92).
The question is whether adults with both disorders should
be treated with MPH despite its misuse potential and the
risks connected to it. In due consideration of the scientific
literature, the benefits of ADHD treatment with MPH outweigh
its risks; therefore, in our opinion, treatment with MPH should
be considered as first-line treatment also in adults with ADHD
and SUD. However, these risks should be seriously taken into
account when planning the therapy. Furthermore, a reasonable
therapeutic setting should be arranged with patients for the
prescription of MPH. Additionally, patients should be closely
monitored for possible side effects andmisuse/diversion ofMPH.
In any case, a verified guideline-based diagnosis is the basic
requirement for the treatment of ADHD. Insights from this
diagnostic procedure can be used to plan the treatment and to
determine the indication of therapy offers (93). The treatment of
ADHD should be adjusted individually for patients with SUDs
as for any other patient. The treatment and its duration can
vary from patient to patient (94). The decision for a treatment
depends on the current severity of ADHD, the psychosocial
impairments, the existing comorbid disorders, and the relevance
of symptoms in the context of existing resources (23, 95). The
treatment with MPH is important, but often not enough. Regular
psychotherapy sessions and specific interventions improve the
success of the treatment significantly (96). Some patients need
treatment with MPH only temporarily or periodically, e.g., when
other compensation strategies are not sufficient anymore or when
they need to face important private or job-related challenges. It is
also relevant to find the adequate formulation, daily dose, and
dosing schedule of MPH to achieve optimal therapeutic results,
which should be verified regularly. However, the approved
drugs and recommended dosages are often not enough to
cover the therapeutic need (95). Because of the lower DAT
availability and occupancy (97), MPH may have reduced efficacy
in persons with SUD (98), especially in cocaine-dependent
ADHD patients (98, 99). Lisdexamfetamine dimesylate (LDX),
as the first long-acting prodrug stimulant for the treatment of
ADHD (100), is possibly another safe and more potent option
for adults with ADHD (101–103). LDX has low misuse potential
due to its biological mechanism of enzymatic hydrolysis to
obtain the active compound D-amphetamine (101). Also, non-
stimulant α2-adrenoceptor agonists, such as guanfacine are an
effective treatment option to be considered, but mainly in the
combined hyperactive/impulsive-inattentive ADHD subgroup
(66). Atomoxetine, a non-stimulant medication, might be
FIGURE 1 | Diagnosis and pharmacotherapy for adult ADHD in patients with
SUD.
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effective for patients with ADHD and alcohol use disorder
(104). However, studies determining the efficacy of these drugs
in adults with ADHD and SUD are scarce. Figure 1 depicts a
step-by-step procedure of diagnosing and treating SUD patients
for ADHD.
In general, extended-release formulations of MPH are
recommended for the treatment of adult ADHD (105), which
may also prevent possible misuse of MPH, due to the lower
misuse potential (77, 78, 106). Luo and Levin state that
also from clinical experience, the misuse liability of long-
acting formulations of prescribed psychostimulants is low (39).
Other methods to prevent misuse are prescribing non-stimulant
drugs (e.g., atomoxetine or guanfacine) or prescribing LDX.
Regular clinical evaluation of MPH adherence and supervising
the intake of medication are additional methods to prevent
misuse (75). In cases of suspected diversion, regular rapid
urine tests can be considered as an instrument to confirm the
intake of medication by the patients. However, the rationale
of these interventions must be clear and should be discussed
with patients in detail as they will experience them as a
violation of their autonomy, which could undermine the
therapeutic relationship.
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